{"name":"Bellerophon Therapeutics","slug":"bellerophon","ticker":"BLPH","exchange":"NASDAQ","domain":"bellerophon.com","description":"Bellerophon Therapeutics (BLPH) is a clinical-stage biotech company focused on pulmonology. The company is developing inhaled nitric oxide therapies for various respiratory indications. BLPH's lead product, INOpulse, is in phase 2 clinical trials. The company has a strong pipeline and is well-positioned to address the growing demand for innovative pulmonology treatments.","hq":"Warren, NJ","founded":0,"employees":"","ceo":"Fabian Tenenbaum","sector":"Clinical-Stage Pulmonology Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$65M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":-19831000,"cash":7935000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Bellerophon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Bellerophon Therapeutics reported its fourth quarter and full year 2023 financial results, highlighting a net loss of $24.6 million and a cash balance of $44.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-06-01","type":"deal","headline":"Bellerophon Therapeutics Announces $20 Million Private Placement","summary":"Bellerophon Therapeutics announced a $20 million private placement to support its ongoing clinical trials and business development efforts.","drugName":"","sentiment":"positive"},{"date":"2022-12-15","type":"regulatory","headline":"Bellerophon Therapeutics Receives FDA Orphan Drug Designation for INOpulse","summary":"Bellerophon Therapeutics received FDA orphan drug designation for its inhaled nitric oxide therapy, INOpulse, for the treatment of pulmonary arterial hypertension.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2024-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-01-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-01-26","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC","headline":"SC 13G Filing","sentiment":"neutral"},{"date":"2024-01-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2024-01-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-12-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-11-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2023-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["United Therapeutics","Gilead Sciences","Insmed"],"therapeuticFocus":["Pulmonology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-19831000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":7935000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}